MedPath

Assessment of effectiveness of Empagliflozin in the management of Anemia in diabetes patients

Phase 3
Conditions
Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications
Registration Number
CTRI/2024/02/063292
Lead Sponsor
SRM Insitute of Science and Technology
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Estimated glomerular filtration rate 45 to 90 ml per minute .

Diabetic patients HbA1C greater than 6.5 percent

Patients with haemoglobin less than 13.0 g per dL in males.

Haemoglobin less than 12.0 g per dL in females.

Exclusion Criteria

End Stage Renal Disease patients Stage 4

Patients with hereditary iron metabolism disorders.

Patients with Type 1 Diabetes mellitus.

Patients with pre-existing Urinary tract or Genital infections and patients who develop this complication during the study.

Patient with pyelonephritis.

Patients already taking diuretics.

Pregnant and Lactating women.

Treatment with any other investigational drug within the previous 30 days of inclusion in the study.

Any therapy or condition that would pose a risk to the patient or make it difficult to comply with study requirements.

Difficulty in Socio Culture Communication.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath